High-affinity peptide targeting trophoblast fine antigen 2 and application of high-affinity peptide
By targeting Trop2's high-affinity peptide and fluorescent probe, combined with near-infrared fluorescent dye MPA, the problem of tumor edge judgment in breast cancer surgery is solved, accurate tumor imaging and image navigation is achieved, and the accuracy of the surgery is improved and efficiency.
Patent Information
- Application Number
- CN202411552607.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-11-01
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-11-01
AI Technical Summary
In breast cancer surgery, it is difficult for the prior art to accurately judge the tumor marginal condition, resulting in missed examination or positive margins. Intraoperative frozen pathological examination takes a long time and is discontinuous, so it is impossible to monitor tumor resection in real time and accurately.
Develop high-affinity peptides and fluorescent probes targeting trophoblast cell surface antigen 2 (Trop2) to target Trop2 receptors, combined with near-infrared fluorescent dye MPA, for tumor imaging and imaging navigation, and achieve tumor boundaries Accurate positioning and intraoperative image navigation.
Accurate imaging and real-time monitoring of Trop2-expressing tumors is achieved, which improves the accuracy and efficiency of the surgery, can quickly reach the tumor site and stay, providing excellent imaging effects, and is suitable for clinical applications.
Smart Images

Figure CN119039391A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biomedical engineering, and in particular relates to a high-affinity peptide targeting trophoblast antigen 2 and an application thereof. Background Art
[0002] The latest global cancer data shows that breast cancer has become the most common cancer in the world. In my country, breast cancer has become a common malignant tumor in women. Breast-conserving surgery is one of the main means of treating early breast cancer. How to accurately remove tumors with clear margins while retaining healthy tissue to the maximum extent without leaving tumor cells is the difficulty of this treatment plan. Currently, doctors judge tumor margins through preoperative imaging, intraoperative visual inspection, palpation, and intraoperative frozen pathology examination. Currently, intraoperative frozen pathology is a more mature method for evaluating tumor margins, but intraoperative frozen pathology is non-continuous sampling, which can easily lead to missed detections and is time-consuming. On the other hand, doctors currently use empirical methods such as intraoperative visual inspection and palpation to guide tumor resection, which may result in positive margins. How to accurately and in real time determine the resection margin status of breast-conserving surgery Trophoblast cell surface antigen 2 (Trop2) is a 323-amino acid transmembrane protein encoded by the TACSTD2 gene, which plays an important role in the proliferation, migration and invasion of tumor cells. Trop2 is highly expressed in a variety of tumors including breast cancer, colorectal cancer, lung cancer and gastric cancer, of which 80% of breast cancer overexpresses Trop2, making this receptor a hot spot for breast tumor treatment and imaging. There are currently no approved Trop2-targeted tracers, and most of the other reported tracers targeting Trop2 are antibodies. Compared with antibodies, peptides have the advantages of weak immunogenicity, rapid distribution in the body, strong penetration, and easy synthesis and modification. Summary of the invention
[0003] The primary purpose of the present invention is to provide a polypeptide and sequence that can target trophoblast cell surface antigen 2 (Trop2), so that it can perform in vivo diagnosis of tumors with high expression of Trop2 receptors and can be used to prepare a new type of targeted drug carrier.
[0004] The present invention also aims to provide several tumor-specific targeted fluorescent probes.
[0005] The present invention also aims to provide uses of the above polypeptides and probes.
[0006] The technical solution adopted by the present invention to achieve the above-mentioned purpose is: The present invention discloses a tumor targeting peptide having the following structure: D n -Gly-Leu-Pro-Tyr-Glu-ABC-NH2; A is selected from Ala, Val, Leu, He, Phe, Trp, Tyr, Asp, Asn, Glu, Lys, Gln, Met, Ser, Thr, Cys, Pro, His or Arg; B is selected from Tyr or D-Tyr; C is selected from Cys or D-Cys; D is selected from Gly, Ala, Val, Leu, Ile, Phe, Trp, Tyr, Asp, Asn, Glu, Lys, Gln, Met, Ser, Thr, Cys, Pro, His or Arg, n is the coupling number of D, n≥0.
[0007] Preferably, 5≥n≥0; or, n is 0, 1, 2, 3, 4 or 5.
[0008] Preferably, A is Ala, Arg or Val, B is Tyr or D-Tyr, C is Cys or D-Cys, D is Gly, Ala, Val, Leu, Ile, Phe, Trp, Tyr, Asp, Asn, Glu, Lys, Gln, Met, Ser, Thr, Cys, Pro, His or Arg, and n=1; or, A is Ala, Arg or Val, B is Tyr or D-Tyr, C is Cys or D-Cys, D is Gly, Ala, Val, Leu, Ile, Phe, Trp, Tyr, Asp, Asn, Glu, Lys, Gln, Met, Ser, Thr, Cys, Pro, His or Arg, n=2; A is Ala, Arg or Val, B is Tyr or D-Tyr, C is Cys or D-Cys, and n=0.
[0009] Preferably, the tumor targeting peptide is selected from YJ-T-01, YJ-T-02, YJ-T-03, YJ-T-04, YJ-T-05, YJ-T-06 or YJ-T-07, YJ-T-01 is Gly-Leu-Pro-Tyr-Glu-Ala-Tyr-Cys-NH2; YJ-T-02 is Gly-Leu-Pro-Tyr-Glu-Arg-Tyr-Cys-NH2; YJ-T-03 is Gly-Leu-Pro-Tyr-Glu-Ala-Tyr-(D-Cys)-NH2; YJ-T-04 is Gly-Leu-Pro-Tyr-Glu-Ala-(D-Tyr)-(D-Cys)-NH2; YJ-T-05 is Gly-Leu-Pro-Tyr-Glu-Val-Tyr-Cys-NH2; YJ-T-06 is Gly-Gly-Leu-Pro-Tyr-Glu-Ala-Tyr-Cys-NH2; YJ-T-07 is Gly-Leu-Gly-Leu-Pro-Tyr-Glu-Ala-Tyr-Cys-NH2.
[0010] The invention discloses use of a tumor targeting peptide in preparing a tumor diagnostic reagent and / or a tumor targeting drug carrier.
[0011] Preferably, the tumor diagnostic agent is a tumor diagnostic imaging agent; or, the tumor diagnostic agent is an imaging agent for precise positioning of tumor boundaries and intraoperative image navigation or a radionuclide imaging agent.
[0012] The invention discloses a probe targeting Trop2 receptor, comprising: a conjugate of the above tumor targeting peptide and a light marker.
[0013] Preferably, the optical marker is selected from at least one of an organic chromophore, an organic fluorophore, a light absorbing compound, a light reflecting compound, a light scattering compound and a bioluminescent molecule; or, the optical marker is selected from at least one of the near-infrared fluorescent dyes MPA, IRDye800, Cy7.5 and Cy5.5.
[0014] The invention discloses use of a probe targeting Trop2 receptor in preparing a tumor diagnostic reagent.
[0015] Preferably, the tumor diagnostic agent is a tumor diagnostic imaging agent; or, the tumor diagnostic agent is an imaging agent for precise positioning of tumor boundaries and intraoperative image navigation or a radionuclide imaging agent.
[0016] The invention discloses a method for preparing a probe targeting a Trop2 receptor, comprising: coupling the above-mentioned tumor targeting peptide with a light marker to prepare the probe targeting a Trop2 receptor.
[0017] The purpose of the present invention can be achieved through the following technical solutions: Tumor targeting peptide, selected from any of the following peptides: YJ-T-01: Gly-Leu-Pro-Tyr-Glu-Ala-Tyr-Cys-NH2; YJ-T-02: Gly-Leu-Pro-Tyr-Glu-Arg-Tyr-Cys-NH2; YJ-T-03: Gly-Leu-Pro-Tyr-Glu-Ala-Tyr-(D-Cys)-NH2; YJ-T-04: Gly-Leu-Pro-Tyr-Glu-Ala-(D-Tyr)-(D-Cys)-NH2; YJ-T-05: Gly-Leu-Pro-Tyr-Glu-Val-Tyr-Cys-NH2; YJ-T-06: Gly-Gly-Leu-Pro-Tyr-Glu-Ala-Tyr-Cys-NH2; YJ-T-07: Gly-Leu-Gly-Leu-Pro-Tyr-Glu-Ala-Tyr-Cys-NH2.
[0018] Application of the tumor targeting peptide of the present invention in the preparation of tumor diagnostic reagents.
[0019] As a preferred embodiment of the present invention, the tumor targeting peptide of the present invention is used in the preparation of tumor diagnostic imaging agents; preferably in the preparation of imaging agents for accurate positioning of tumor boundaries and intraoperative image navigation or in the preparation of radionuclide imaging agents.
[0020] A probe targeting Trop2 receptor is a conjugate of the tumor targeting peptide of the present invention and a light marker.
[0021] Preferably, the optical label is selected from the group consisting of organic chromophores, organic fluorophores, light absorbing compounds, light reflecting compounds, light scattering compounds and bioluminescent molecules.
[0022] Preferably, the near-infrared fluorescent dye is selected from the near-infrared fluorescent dyes MPA, IRDye800, Cy7.5, and Cy5.5; MPA is further preferred.
[0023] The invention also discloses a method for preparing the polypeptide, including resin pretreatment, preparation of amino acid reagent activation solution, synthesis of polypeptide resin and preparation of the polypeptide.
[0024] Preferably, in the resin pretreatment, the Rink Amide MBHA resin is mixed with DCM for swelling treatment, and then the swollen resin is mixed with a deprotection solution for deprotection treatment to obtain a pretreated resin. During the swelling treatment, nitrogen is blown for 10-30 minutes to fully swell the resin, and then the DCM is removed, washed with DMF, and dried; the DCM must be submerged in the RinkAmide MBHA resin during use.
[0025] More preferably, in the resin pretreatment, the deprotection solution is a DMF solution containing 10-30wt% hexahydropyridine. In the deprotection treatment, the deprotection is carried out for 5-30 minutes, the deprotection solution is removed, the resin is drained, and then washed with DMF, DCM, and DMF in sequence and drained. The deprotection solution must be submerged in the Rink Amide MBHA resin.
[0026] Preferably, in the preparation of the amino acid reagent activation solution, the amino acid reagent and HBTU are added to DMF, and then DIPEA is added for activation for 10-60 min to obtain the amino acid reagent activation solution.
[0027] More preferably, in the preparation of the amino acid reagent activation solution, the amount of the amino acid reagent used is 2-10 wt % of DMF.
[0028] More preferably, in the preparation of the amino acid reagent activation solution, the molar amount of HBTU used is 50-300% of the molar amount of the amino acid reagent used.
[0029] More preferably, in the preparation of the amino acid reagent activation solution, the molar amount of DIPEA used is 50-300% of the molar amount of the amino acid reagent used, and the amino acid reagent includes any one of the following: Fmoc-Cys(Trt)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Ala-OH, Fmoc-Glu(otBu)-OH, Fmoc-Pro-OH, Fmoc-Leu-OH, Fmoc-Gly-OH, Fmoc-Arg(Pbf)-OH, and Fmoc-Val-OH.
[0030] Preferably, in the synthesis of the polypeptide resin, the pretreated resin is mixed with the first amino acid reagent activation solution, the coupling reaction is carried out for 10-60 minutes, and after the reaction is completed, it is washed and dried, and then the deprotection treatment and amino acid coupling are repeated in sequence according to the polypeptide sequence until the last amino acid is coupled, washed with methanol, and fully dried in a vacuum drying oven to obtain a polypeptide resin.
[0031] More preferably, in the synthesis of the polypeptide resin, the amount of the first amino acid reagent activation solution used is measured by the amino acid reagent therein, and the molar amount of the first amino acid reagent used is 100-500% of the total molar amount of the degree of substitution on the pretreated resin; in the subsequent coupling treatment, the pretreated resin coupled with the amino acid is measured by the amount of the pretreated resin initially used, and the amount of the amino acid reagent activation solution used is measured by the amino acid reagent therein, and the molar amount of the amino acid reagent used is 100-500% of the total molar amount of the degree of substitution on the pretreated resin.
[0032] More preferably, in the synthesis of the polypeptide resin, the washing after the reaction is completed is sequentially performed with DMF, DCM, and DMF. The amino acid coupling is to mix the amino acid reagent activation solution to be coupled with the resin after the previous step of deprotection, and perform the coupling of the amino acid reagent.
[0033] More preferably, in the synthesis of the polypeptide resin, after the amino acid coupling is completed, the free amino group can be detected by the following method: take a small amount of polypeptide resin to which the amino acid with the protective group is coupled, add one drop each of an ethanol solution containing 6wt% ninhydrin and an ethanol solution containing 80wt% phenol for detection. If the condensation is complete and there is no free amino group, the solution will be colorless or light yellow; otherwise, the polypeptide resin or solution will turn blue or reddish brown, indicating that the reaction is incomplete.
[0034] Preferably, in the preparation of the polypeptide, the polypeptide resin is mixed with the lysate, shaken at 0-10°C for 1-5h, the resin is separated to obtain the solution, transferred to ice anhydrous ether, naturally precipitated, centrifuged to obtain the solid, washed with ether, and dried to obtain a crude polypeptide product; the crude polypeptide product is purified and separated by liquid chromatography to obtain the polypeptide.
[0035] More preferably, in the preparation of the polypeptide, the lysis solution is a mixture of trifluoroacetic acid, thioanisole, ethanedithiol, phenol and water, and the lysis solution contains 80-90wt% of trifluoroacetic acid, 3-8wt% of thioanisole, 1-4wt% of ethanedithiol, 1-4wt% of phenol, and the balance of water.
[0036] The invention discloses a method for preparing an MPA-polypeptide, including the activation of MPA, the preparation of PEG-polypeptide and the preparation of MPA-polypeptide.
[0037] Preferably, in the activation of MPA, MPA is added to DMSO, and then EDCI and NHS are added, and the reaction is carried out in the dark for 2-8 hours to perform a carboxyl activation reaction to obtain an activated MPA solution.
[0038] More preferably, in the activation of MPA, the amount of MPA added to DMSO is 0.05-0.2 mol / L.
[0039] More preferably, in the activation of MPA, the molar amount of EDCI used is 100-300% of the molar amount of MPA used.
[0040] More preferably, in the activation of MPA, the molar amount of NHS used is 100-300% of the molar amount of MPA used.
[0041] Preferably, in the preparation of PEG-polypeptide, the solid phase synthesized polypeptide, Fmoc-PEG4-propionic acid, and HATU are added to DMF, dissolved and then added with DIPEA, and reacted at 20-40°C for 0.5-2h. After the reaction is completed, it is diluted with water and separated and purified by HPLC, and deprotected with a deprotection solution to obtain PEG-YJ-T-01.
[0042] More preferably, in the preparation of PEG-polypeptide, the amount of polypeptide added to DMF is 0.05-0.2 mol / L.
[0043] More preferably, in the preparation of PEG-polypeptide, the molar amount of Fmoc-PEG4-propionic acid used is 200-500% of the polypeptide.
[0044] More preferably, in the preparation of PEG-polypeptide, HATU is used in a molar amount of 200-500% of the polypeptide.
[0045] More preferably, in the preparation of PEG-polypeptide, the molar amount of DIPEA used is 200-500% of the polypeptide.
[0046] More preferably, in the preparation of PEG-polypeptide, the deprotection solution is piperidine / DMF, and piperidine and DMF in the deprotection solution are mixed in a volume ratio of 1:2-6.
[0047] Preferably, in the preparation of MPA-polypeptide, PEG-polypeptide and triethylamine are added to DMSO, reacted under nitrogen protection for 10-30 minutes, and then activated MPA solution is added, reacted at 20-40° C. for 6-24 hours. After the reaction is completed, freeze-dried and concentrated, then diluted with water, separated and purified by HPLC to prepare MPA-polypeptide.
[0048] More preferably, in the preparation of MPA-polypeptide, the amount of PEG-polypeptide added to DMSO is 0.05-0.2 mol / L.
[0049] More preferably, in the preparation of MPA-polypeptide, the molar amount of triethylamine used is 300-800% of the molar amount of PEG-polypeptide used.
[0050] More preferably, in the preparation of MPA-polypeptide, the amount of activated MPA solution used is measured based on the amount of MPA therein, and the molar amount of MPA used is 100-300% of the molar amount of PEG-polypeptide used.
[0051] The probe targeting Trop2 receptor of the present invention is used in the preparation of tumor diagnostic reagents; preferably in the preparation of tumor diagnostic imaging agents; further preferably in the preparation of precise positioning of tumor boundaries and intraoperative image navigation imaging agents or in the preparation of radionuclide imaging agents.
[0052] Application of the tumor targeting peptide of the present invention in preparing tumor targeting drug carriers.
[0053] The polypeptide compound of the present invention specifically targets trophoblast cell surface antigen 2 (Trop2) to the tumor site, and has good aggregation and retention at the tumor site, has a high target and non-target ratio, is suitable for use as a fluorescent tumor imaging agent, and can be used to prepare optical imaging drugs for intraoperative image navigation of tumors and precise positioning of tumor boundaries.
[0054] The present invention has developed a polypeptide targeting trophoblast cell surface antigen 2 (Trop2), which utilizes the high expression of Trop2 receptors in breast tumors to target and identify tumor cells. These polypeptides are all low molecular weight polypeptides, which can quickly reach the tumor site and stay there, thereby obtaining a good tumor imaging effect. At the same time, the polypeptide has a low synthesis cost and is easy to obtain, making it more conducive to clinical promotion and application. The polypeptide disclosed in the present invention can specifically bind to tumor cells, and has excellent imaging effects on triple-negative breast tumors as confirmed by in vivo optical imaging and results. The present invention utilizes the advantages of the near-infrared fluorescent dye MPA with a deeper penetration depth and weaker background tissue autofluorescence, and has good application prospects in fluorescence imaging and fluorescence-guided surgery. Polypeptide radiopharmaceuticals can be used for screening and early diagnosis of tumors, and can also be used for real-time, non-destructive, in-situ monitoring of early malignant tumors and treatment. BRIEF DESCRIPTION OF THE DRAWINGS
[0055] Figure 1 This is a curve diagram of the interaction between YJ-T-01 polypeptide and Trop2.
[0056] Figure 2 It is a liquid chromatogram.
[0057] Figure 3 This is the molecular ion peak diagram of MPA-YJ-T-01.
[0058] Figure 4 This is the half peak diagram of MPA-YJ-T-01.
[0059] Figure 5 Optical imaging of single dye MPA and compound MPA-YJ-T-01 in breast cancer HCC1806 tumor-bearing mice.
[0060] Figure 6 Optical imaging of single dye MPA and compound MPA-YJ-T-02 in breast cancer HCC1806 tumor-bearing mice.
[0061] Figure 7 The in vivo tumor targeting effect of the dye MPA alone and the compound MPA-YJ-T-01 and the expression level of Trop2.
[0062] Figure 8Surgical navigation for the compound MPA-YJ-T-01 in mice bearing breast cancer MDA-MB-231 tumors. DETAILED DESCRIPTION
[0063] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0064] The following first describes the concepts involved in the present application in conjunction with the accompanying drawings. It should be noted that the following description of each concept is only to make the content of the present application easier to understand, and does not limit the scope of protection of the present application; at the same time, the embodiments and features in the embodiments of the present application can be combined with each other in the absence of conflict. The present application will be described in detail with reference to the accompanying drawings and in conjunction with the embodiments.
[0065] Example 1: A method for preparing a polypeptide The polypeptide prepared in this example is numbered YJ-T-01, and the sequence is Gly-Leu-Pro-Tyr-Glu-Ala-Tyr-Cys-NH2.
[0066] Resin pretreatment: Rink Amide MBHA resin is mixed with DCM for swelling treatment, and then the swollen resin is mixed with a deprotection solution for deprotection treatment to obtain a pretreated resin. During the swelling treatment, nitrogen is blown for 30 minutes to fully swell the resin, and then DCM is removed, washed with DMF, and dried; DCM must be submerged in the Rink Amide MBHA resin during use. The deprotection solution is a DMF solution containing 20wt% hexahydropyridine. During the deprotection treatment, deprotection is performed for 10 minutes, the deprotection solution is removed, and dried, and then washed with DMF, DCM, and DMF in sequence, and dried; the deprotection solution must be submerged in the Rink Amide MBHA resin during use.
[0067] Preparation of amino acid reagent activation solution: add amino acid reagent and HBTU into DMF, then add DIPEA for activation for 30 minutes to obtain amino acid reagent activation solution. The amount of amino acid reagent used is 4wt% of DMF, the molar amount of HBTU used is 100% of the molar amount of amino acid reagent used, the molar amount of DIPEA used is 100% of the molar amount of amino acid reagent used, and the amino acid reagent includes any one of the following: Fmoc-Cys(Trt)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Ala-OH, Fmoc-Glu(otBu)-OH, Fmoc-Pro-OH, Fmoc-Leu-OH, Fmoc-Gly-OH.
[0068] Synthesis of peptide resin: Mix the pretreated resin with the first amino acid reagent activation solution, and allow the coupling reaction to proceed for 30 minutes. After the reaction is completed, wash and drain, and then repeat the deprotection treatment and amino acid coupling in order according to the YJ-T-01 peptide sequence until the last amino acid Fmoc-Gly-OH is coupled, wash with methanol, and fully dry in a vacuum drying oven to obtain a peptide resin. The first amino acid reagent activation solution is an amino acid reagent activation solution of Fmoc-Cys(Trt)-OH. The amount of the amino acid reagent activation solution used is measured by the amino acid reagent therein, and the molar amount of Fmoc-Cys(Trt)-OH used is 300% of the total molar amount of substitution on the pretreated resin; in the subsequent coupling treatment, the pretreated resin coupled with amino acids is measured by the amount of the pretreated resin initially used, and the amount of the amino acid reagent activation solution used is measured by the amino acid reagent therein, and the molar amount of the amino acid reagent used is 300% of the total molar amount of substitution on the pretreated resin; after the reaction is completed, washing is performed in sequence with DMF, DCM, and DMF. Amino acid coupling is to mix the amino acid reagent activation solution to be coupled with the resin after deprotection in the previous step, and then couple the amino acid reagent. The order of use of amino acid reagents in the preparation of YJ-T-01 polypeptide is: Fmoc-Cys(Trt)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Ala-OH, Fmoc-Glu(otBu)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Pro-OH, Fmoc-Leu-OH, Fmoc-Gly-OH. After the amino acid coupling is completed, the free amino group can be detected by the following method: take a small amount of polypeptide resin with amino acids with protective groups, add one drop of 6wt% ninhydrin ethanol solution and one drop of 80wt% phenol ethanol solution for detection. If the condensation is complete and there is no free amino group, the solution will be colorless or light yellow; otherwise, the polypeptide resin or solution will turn blue or reddish brown, indicating that the reaction is incomplete.
[0069] Preparation of polypeptide: Mix the polypeptide resin with the lysate, shake at 0°C for 3h, separate the resin to obtain the solution, transfer it to ice anhydrous ether, naturally settle, centrifuge to obtain the solid, wash with ether, and dry to obtain a crude polypeptide product; use liquid chromatography to purify and separate the crude polypeptide product to obtain the YJ-T-01 polypeptide. Determine the mass-to-charge ratio of the YJ-T-01 polypeptide and determine the molecular weight [M+H] + =914.6. The lysate is a mixture of trifluoroacetic acid, thioanisole, ethanedithiol, phenol and water, and the lysate contains 87.5wt% trifluoroacetic acid, 5wt% thioanisole, 2.5wt% ethanedithiol, 2.5wt% phenol, and the remainder of water. The liquid chromatography is a high performance liquid chromatography. In the purification and separation, a C18 column with a chromatographic filler of 10 μm is used, the mobile phase A is an aqueous solution containing 0.1wt% TFA, and the mobile phase B is an acetonitrile solution containing 0.1wt% TFA. Gradient elution and cyclic injection purification are used, the eluted product of the main peak is collected, and the acetonitrile is evaporated to complete the purification and separation.
[0070] Example 2: A method for preparing a polypeptide The polypeptide prepared in this example is numbered YJ-T-02, and the sequence is Gly-Leu-Pro-Tyr-Glu-Arg-Tyr-Cys-NH2.
[0071] The preparation method of the YJ-T-02 polypeptide in this example is basically the same as that in Example 1, except for the preparation of the amino acid reagent activation solution and the synthesis of the polypeptide resin. In the preparation of the amino acid reagent activation solution, Fmoc-Ala-OH is replaced with Fmoc-Arg(Pbf)-OH. In the synthesis of the polypeptide resin, the amino acid reagents are coupled in order according to the sequence of the YJ-T-02 polypeptide.
[0072] Example 3: A method for preparing a polypeptide The polypeptide prepared in this example is numbered YJ-T-03, and the sequence is Gly-Leu-Pro-Tyr-Glu-Ala-Tyr-(D-Cys)-NH2.
[0073] The preparation method of the YJ-T-03 polypeptide in this example is basically the same as that in Example 1, except for the preparation of the amino acid reagent activation solution and the synthesis of the polypeptide resin. In the preparation of the amino acid reagent activation solution, Fmoc-Cys(Trt)-OH is replaced with Fmoc-D-Cys(Trt)-OH. In the synthesis of the polypeptide resin, the amino acid reagents are coupled in order according to the sequence of the YJ-T-03 polypeptide.
[0074] Example 4: A method for preparing a polypeptide The polypeptide prepared in this example is numbered YJ-T-04, and the sequence is Gly-Leu-Pro-Tyr-Glu-Ala-(D-Tyr)-(D-Cys)-NH2.
[0075] The preparation method of the YJ-T-04 polypeptide in this example is basically the same as that in Example 1, except for the preparation of the amino acid reagent activation solution and the synthesis of the polypeptide resin. In the preparation of the amino acid reagent activation solution, Fmoc-Ala-OH is replaced with Fmoc-D-Tyr(tBu)-OH. In the synthesis of the polypeptide resin, the amino acid reagents are coupled in order according to the sequence of the YJ-T-04 polypeptide.
[0076] Example 5: A method for preparing a polypeptide The polypeptide prepared in this example is numbered YJ-T-05, and the sequence is Gly-Leu-Pro-Tyr-Glu-Val-Tyr-Cys-NH2.
[0077] The preparation method of the YJ-T-05 polypeptide in this example is basically the same as that in Example 1, except for the preparation of the amino acid reagent activation solution and the synthesis of the polypeptide resin. In the preparation of the amino acid reagent activation solution, Fmoc-Ala-OH is replaced with Fmoc-Val-OH. In the synthesis of the polypeptide resin, the amino acid reagents are coupled in order according to the sequence of the YJ-T-05 polypeptide.
[0078] Example 6: A method for preparing a polypeptide The polypeptide prepared in this example is numbered YJ-T-06, and the sequence is Gly-Gly-Leu-Pro-Tyr-Glu-Ala-Tyr-Cys-NH2.
[0079] The preparation method of the YJ-T-06 polypeptide in this example is basically the same as that in Example 1, except for the synthesis of the polypeptide resin. In the synthesis of the polypeptide resin, the amino acid reagents are coupled in order according to the sequence of the YJ-T-06 polypeptide.
[0080] Example 7: A method for preparing a polypeptide The polypeptide prepared in this example is numbered YJ-T-07, and the sequence is Gly-Leu-Gly-Leu-Pro-Tyr-Glu-Ala-Tyr-Cys-NH2.
[0081] The preparation method of the YJ-T-07 polypeptide in this example is basically the same as that in Example 1, except for the synthesis of the polypeptide resin. In the synthesis of the polypeptide resin, the amino acid reagents are coupled in order according to the sequence of the YJ-T-07 polypeptide.
[0082] Comparative Example 1: A method for preparing a polypeptide The polypeptide prepared in this comparative example is numbered YJ-T-08, and the sequence is Gly-Leu-Pro-Tyr-Glu-Gly-Tyr-Cys-NH2.
[0083] The preparation method of the YJ-T-08 polypeptide in this comparative example is basically the same as that in Example 1, except for the synthesis of the polypeptide resin. In the synthesis of the polypeptide resin, the amino acid reagents are coupled in order according to the sequence of the YJ-T-08 polypeptide.
[0084] Comparative Example 2: A method for preparing a polypeptide The polypeptide prepared in this comparative example is numbered YJ-T-09, and the sequence is Gly-Leu-Pro-Tyr-Glu-Ala-Tyr-Cys-Leu-NH2.
[0085] The preparation method of the YJ-T-09 polypeptide in this comparative example is basically the same as that in Example 1, except for the synthesis of the polypeptide resin. In the synthesis of the polypeptide resin, the amino acid reagents are coupled in order according to the sequence of the YJ-T-09 polypeptide.
[0086] Comparative Example 3: A method for preparing a polypeptide The polypeptide prepared in this comparative example is numbered YJ-T-10, and the sequence is Gly-Leu-Pro-Tyr-Glu-Ala-Tyr-Cys-Leu-Pro-NH2.
[0087] The preparation method of the YJ-T-10 polypeptide in this comparative example is basically the same as that in Example 1, except for the synthesis of the polypeptide resin. In the synthesis of the polypeptide resin, the amino acid reagents are coupled in order according to the sequence of the YJ-T-10 polypeptide.
[0088] Experimental Example 1: Detection of the affinity between peptide and Trop2 protein by surface plasmon resonance (SPR) method Surface plasmon resonance (SPR) is a method for characterizing molecular interactions. Biotin-Trop2 was coated on the SA chip, and the non-labeled test peptide solution was diluted into 8 concentration gradients. After 180 seconds of binding and dissociation reaction, the reaction curve was automatically analyzed by the biacore system. The results of the YJ-T-01 peptide prepared in Example 1 are shown in Figure 2. Figure 1 As shown, the molecular binding degree was calculated to obtain the affinity between YJ-T-01 polypeptide and Trop2 protein.
[0089] The polypeptides prepared in Examples 2-7 of the present invention all have good affinity for Trop2 protein, while the polypeptides prepared in Comparative Examples 1-3 have poor affinity for Trop2 protein.
[0090] Example 8: A method for preparing a fluorescent targeting compound In this example, MPA-YJ-T-01 is prepared by combining YJ-T-01 polypeptide and MPA.
[0091] Activation of MPA: Take 0.02 mmol MPA and dissolve it in 200 μL ultra-dry DMSO, add 3.7 mg 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and 2.2 mg N-hydroxysuccinimide (EDCI / NHS) (molar ratio MPA:EDCI:NHS=1:1.5:1.5), react in the dark for 4 hours, carry out carboxyl activation reaction, and obtain activated MPA solution.
[0092] Preparation of PEG-YJ-T-01: Take 0.02 mmol of the solid-phase synthesized peptide YJ-T-01, 0.06 mmol of Fmoc-PEG4-propionic acid and 0.06 mmol of HATU, add them into 200 μL of DMF, add 0.12 mmol of DIPEA after dissolution, react at 25°C for 0.5 h, dilute with water after the reaction, separate and purify by HPLC to prepare Fmoc-PEG-YJ-T-01, and use piperidine / DMF (volume ratio of piperidine:DMF=1:4) for deprotection to obtain PEG-YJ-T-01.
[0093] Preparation of MPA-YJ-T-01: Take 0.02mmol of PEG-YJ-T-01 and 0.1mmol of triethylamine and add them to 200μL ultra-dry DMSO, and react for 10min under nitrogen protection; add activated MPA solution and stir the reaction at room temperature for 12h; after the reaction, concentrate the reaction solution by freeze-drying, then add distilled water to dilute it, and use liquid phase for separation and purification. The liquid phase conditions are as follows: Agilent1220 Infinity II series HPLC system, equipped with Agilent ZORBAX SB-C18 semi-preparative column (9.4×250mm, 5μm), gradient elution for 60min, flow rate 2mL / min, wherein mobile phase A is ultrapure water containing 0.01wt% TFA, and mobile phase B is acetonitrile containing 0.01wt% TFA. The elution gradient was set as follows: 95% A and 5% B at 0-5 minutes, 85% A and 15% B at 15 minutes, 70% A and 30% B at 30 minutes, 50% A and 50% B at 45 minutes, and 10% A and 90% B at 60 minutes. The final product was confirmed to be MPA-YJ-T-01 by HPLC and ESI-MS mass spectrometry analysis. The HPLC chart is shown in Figure 2 The molecular ion peak of MPA-YJ-T-01 in ESI-MS mass spectrometry analysis is shown in Figure 3 , MPA-YJ-T-01 half peak of ESI-MS mass spectrometry analysis can be found at Figure 4 .
[0094] Example 9: A method for preparing a fluorescent targeting compound In this example, MPA-YJ-T-02 is prepared by combining YJ-T-02 polypeptide and MPA.
[0095] The preparation methods of this embodiment are basically the same as those of embodiment 8, except that MPA-YJ-T-01 is replaced with MPA-YJ-T-02 to prepare MPA-YJ-T-02.
[0096] Experimental Example 2: Optical imaging of compound MPA-YJ-T-01 in breast cancer HCC1806 tumor-bearing mice The compound MPA-YJ-T-01 prepared in Example 8 was added to physiological saline to prepare an MPA-YJ-T-01 solution with a concentration of 250 μg / mL. Three nude mice bearing breast cancer HCC1806 weighing about 20 grams were injected with 100 μL of the compound MPA-YJ-T-01 solution through the tail vein. Optical signal collection was performed 2h, 4h, 6h, 8h, 10h and 12h after administration. A control group was set up, and the compound MPA-YJ-T-01 was replaced with a single dye MPA with the same molar concentration. The distribution of the probe in the mouse body and its enrichment in the tumor area were observed. It can be seen from the imaging image of the compound MPA-YJ-T-01 at 2h that the probe has been significantly aggregated in the tumor, and then remained in the tumor until 12h. The imaging results are shown in the following figure. Figure 5 As shown, sample 1 is a single dye MPA, and sample 2 is a compound MPA-YJ-T-01. Among them, the probe is more enriched in the tumor site at 8h, while the uptake and clearance of other background signals are faster. From the signal of the bladder, it can be inferred that this probe is mainly metabolized by the kidney.
[0097] Experimental Example 3: Optical imaging of compound MPA-YJ-T-02 in breast cancer HCC1806 tumor-bearing mice.
[0098] The compound MPA-YJ-T-02 prepared in Example 9 was added to physiological saline to prepare an MPA-YJ-T-02 solution with a concentration of 250 μg / mL. Three nude mice bearing breast cancer HCC1806 weighing about 20 grams were injected with 100 μL of the compound MPA-YJ-T-02 solution through the tail vein, and optical signal collection was performed 2h, 4h, 6h, 8h, 10h and 12h after administration. A control group was set up, and the compound MPA-YJ-T-02 was replaced with a single dye MPA with the same molar concentration. The distribution of the probe in the mouse body and its enrichment in the tumor area were observed. It can be seen from the imaging image of the compound MPA-YJ-T-01 at 2h that the probe has been obviously aggregated in the tumor, but there are also signals in other parts. After that, the signal in the tumor lasts until 12h, and other background signals are cleared and metabolized. The imaging results are as follows. Figure 6 As shown, sample 1 is a single dye MPA, and sample 3 is a compound MPA-YJ-T-02. In sample 3, the probe has a clear outline at the edge of the tumor 12 hours after injection. From the signal of the bladder, it can be inferred that this probe is mainly metabolized by the kidneys.
[0099] The polypeptides of Examples 3-7 of the present invention can also be coupled with MPA and used for in vivo optical imaging.
[0100] Experimental Example 4: In vivo tumor targeting effect of fluorescent targeting compounds and Trop2 expression level A mouse model of HCC1806 bilateral breast cancer with differential Trop2 expression was constructed. HCC1806-sg-GFP cells with normal Trop2 expression and HCC1806-sg-2 cells with Trop2 knockdown were injected into the left and right mammary glands of nude mice, respectively. The number of injected cells was 1×10 6 After 12 days, a bilateral breast cancer tumor-bearing mouse model with differential Trop2 expression was obtained.
[0101] The test results are as follows Figure 7 As shown, A is the verification of Trop2 expression level of cells by western blotting, where sg-GFP refers to empty-loaded HCC1806-sg-GFP cells with normal Trop2 expression, sg-1 refers to Trop2 knockdown HCC1806 cells No. 1, and sg-2 refers to Trop2 knockdown HCC1806-sg-2 cells No. 2. The results showed that the Trop2 expression level of HCC1806-sg-2 cells was significantly lower than that of HCC1806-sg-GFP cells.
[0102] Sample 1 in B is a single dye MPA, sample 2 is a compound MPA-YJ-T-01, the left breast tumor is a HCC1806-sg-GFP tumor with normal Trop2 expression, and the right breast tumor is a HCC1806-sg-2 tumor with Trop2 knockdown. The compound MPA-YJ-T-01 prepared in Example 8 was added to normal saline to prepare a MPA-YJ-T-01 solution with a concentration of 250 μg / mL. Three bilateral breast cancer tumor-bearing mice weighing about 20 grams with different Trop2 expressions were injected with 100 μL of the compound MPA-YJ-T-01 solution through the tail vein, and optical signals were collected at 2h, 4h, 6h, 8h, 10h, 12h and 24h after administration. After 24h, the model mice were dissected and the tumor tissue was ex vivo for optical signal collection. A control group was set up, and the compound MPA-YJ-T-01 was replaced with a single dye MPA with the same molar concentration. The distribution of the probe in the mouse body and its enrichment in different tumor areas were observed. The results showed that in the same model mouse, the compound MPA-YJ-T-01 was significantly aggregated in the left breast tumor with normal Trop2 expression, and the fluorescence intensity was significantly reduced in the right breast tumor with Trop2 knockdown, indicating that the compound MPA-YJ-T-01 has a certain degree of in vivo Trop2 targeting and specificity. At the same time, in the control group, the dye MPA did not accumulate significantly in bilateral tumors.
[0103] Experimental Example 5: Surgical navigation of compound MPA-YJ-T-01 in breast cancer MDA-MB-231 tumor-bearing mice The compound MPA-YJ-T-01 prepared in Example 8 was added to physiological saline to prepare a MPA-YJ-T-01 solution with a concentration of 250 μg / mL. 100 μL of the compound MPA-YJ-T-01 solution was injected into three nude mice bearing breast cancer MDA-MB-231 weighing about 20 grams through the tail vein, and optical signal collection was performed at 2h, 4h, 6h, 8h, 10h, 12h and 24h after administration. The distribution of the probe in the mouse body and its enrichment in the tumor area were observed. The imaging image of the compound MPA-YJ-T-01 at 2h had accumulated in the tumor and remained until 24h. At 8h, the edge contour of the tumor began to appear clearer. The imaging results are shown in Figure 2. Figure 8 As shown, sample 2 is compound MPA-YJ-T-01. Sample 2 was surgically removed under the guidance of a fluorescent probe 24 hours after injection, and a residual focus was removed in addition to the main tumor focus.
[0104] The polypeptides of Examples 2-7 of the present invention can also be coupled with MPA and used for in vivo surgical navigation.
[0105] The polypeptides of Examples 1-7 of the present invention can be used for in vivo diagnosis of tumors in vivo and for preparing novel targeted drug carriers; the polypeptide-MPA conjugates can be used as fluorescent probes specifically targeting tumors in vivo.
[0106] The embodiments and / or implementation methods described above are only used to illustrate the preferred embodiments and / or implementation methods for realizing the technology of the present invention, and are not intended to limit the implementation methods of the technology of the present invention in any form. Any technical personnel in this field may make slight changes or modifications to other equivalent embodiments without departing from the scope of the technical means disclosed in the content of the present invention, but they should still be regarded as technologies or embodiments that are essentially the same as the present invention.
[0107] This article uses specific examples to illustrate the principles and implementation methods of this application. The description of the above embodiments is only used to help understand the method and its core ideas of this application. The above is only the preferred implementation method of this application. It should be pointed out that due to the limitations of textual expression and the objective existence of infinite specific structures, ordinary technicians in this technical field can make several improvements, modifications or changes without departing from the principles of this application, and can also combine the above technical features in an appropriate manner; these improvements, modifications, changes or combinations, or the direct application of the concept and technical solution of the invention to other occasions without improvement, should be regarded as the scope of protection of this application.
Claims
1. A tumor targeting peptide having the following structure: D n -Gly-Leu-Pro-Tyr-Glu-A-B-C-NH2; A is selected from Ala, Val, Leu, He, Phe, Trp, Tyr, Asp, Asn, Glu, Lys, Gln, Met, Ser, Thr, Cys, Pro, His or Arg; B is selected from Tyr or D-Tyr; C is selected from Cys or D-Cys; D is selected from Gly, Ala, Val, Leu, Ile, Phe, Trp, Tyr, Asp, Asn, Glu, Lys, Gln, Met, Ser, Thr, Cys, Pro, His or Arg, n is the coupling number of D, n≥0.
2. A tumor targeting peptide according to claim 1, characterized in that: 5≥n≥0; or, n is 0, 1, 2, 3, 4 or 5.
3. A tumor targeting peptide according to claim 1 or 2, characterized in that: A is Ala, Arg or Val, B is Tyr or D-Tyr, C is Cys or D-Cys, D is Gly, Ala, Val, Leu, Ile, Phe, Trp, Tyr, Asp, Asn, Glu, Lys, Gln, Met, Ser, Thr, Cys, Pro, His or Arg, and n=1; or, A is Ala, Arg or Val, B is Tyr or D-Tyr, C is Cys or D-Cys, D is Gly, Ala, Val, Leu, Ile, Phe, Trp, Tyr, Asp, Asn, Glu, Lys, Gln, Met, Ser, Thr, Cys, Pro, His or Arg, and n=2; A is Ala, Arg or Val, B is Tyr or D-Tyr, C is Cys or D-Cys, and n=0.
4. A tumor targeting peptide according to claim 1 or 2, characterized in that: The tumor targeting peptide is selected from YJ-T-01, YJ-T-02, YJ-T-03, YJ-T-04, YJ-T-05, YJ-T-06 or YJ-T-07, YJ-T-01 is Gly-Leu-Pro-Tyr-Glu-Ala-Tyr-Cys-NH2; YJ-T-02 is Gly-Leu-Pro-Tyr-Glu-Arg-Tyr-Cys-NH2; YJ-T-03 is Gly-Leu-Pro-Tyr-Glu-Ala-Tyr-(D-Cys)-NH2; YJ-T-04 is Gly-Leu-Pro-Tyr-Glu-Ala-(D-Tyr)-(D-Cys)-NH2; YJ-T-05 is Gly-Leu-Pro-Tyr-Glu-Val-Tyr-Cys-NH2; YJ-T-06 is Gly-Gly-Leu-Pro-Tyr-Glu-Ala-Tyr-Cys-NH2; YJ-T-07 is Gly-Leu-Gly-Leu-Pro-Tyr-Glu-Ala-Tyr-Cys-NH2.
5. Use of the tumor targeting peptide according to claim 1 in the preparation of tumor diagnostic reagents and / or tumor targeting drug carriers.
6. The use according to claim 5, characterized in that: The tumor diagnostic reagent is a tumor diagnostic imaging agent; or, the tumor diagnostic reagent is an imaging agent for accurate positioning of tumor boundaries and intraoperative image navigation or a radionuclide imaging agent for preparation.
7. A probe targeting a Trop2 receptor, comprising: The conjugate of the tumor targeting peptide and a light marker as claimed in claim 1.
8. A probe targeting Trop2 receptor according to claim 7, characterized in that: The optical marker is selected from at least one of an organic chromophore, an organic fluorophore, a light absorbing compound, a light reflecting compound, a light scattering compound and a bioluminescent molecule; or, the optical marker is selected from at least one of near-infrared fluorescent dyes MPA, IRDye800, Cy7.5 and Cy5.
5.
9. Use of a probe targeting Trop2 receptor according to claim 7 or 8 in the preparation of tumor diagnostic reagents.
10. A method for preparing a probe targeting a Trop2 receptor, comprising: The probe targeting the Trop2 receptor is prepared by coupling the tumor targeting peptide described in claim 1 with a photolabel.
Citation Information
Patent Citations
Anti-TROP2 nano antibody as well as preparation method and application thereof
CN112321715A
High-affinity peptide targeting hepatocyte growth factor and application thereof
CN112480212A
Series of TROP-2 protein targeting polypeptides
CN115700257A
High-affinity Trop2 targeting multi-element cyclic peptide molecular framework
CN116199746A
Tumor high-affinity peptide YQP-4 and application thereof
CN116375804A
